期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.724815
关键词
pancreatic cancer; brain metastases; ALK Kinase; EML4-ALK fusion protein; crizotinib; alectinib
类别
资金
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2019PT310026]
This study reported a 34-year-old patient with ALK rearrangement-positive and KRAS-wild pancreatic cancer, who showed significant responses to targeted therapies after developing resistance to chemotherapy, indicating that comprehensive molecular profiling for guiding targeted therapies can significantly improve survival outcomes for a subgroup of patients with pancreatic cancer.
Patients with metastatic pancreatic cancer typically have poor prognosis due to the limited effectiveness of existing treatment options. ALK rearrangement-positive is rare in pancreatic cancer, but may occur in those with KRAS-wild type. We present a 34-year-old young man with ALK rearrangement-positive and KRAS-wild pancreatic cancer who had a remarkable response to crizotinib after resistance to prior chemotherapy and re-response to alectinib after brain metastases developed. This clinical observation suggests that comprehensive molecular profiling to guide targeted therapies is not only feasible, but also significantly improves survival outcomes for a subgroup of patients with pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据